Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial-Reference-Cited by-同舟云学术

Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial

Published:2016-05 Issue: Volume:175 Page:18-27
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Shimada Yuichi J.,Cannon Christopher P.,Liu Yuyin,Wilson Craig,Kupfer Stuart,Menon Venu,Cushman William C.,Mehta Cyrus R.,Bakris George L.,Zannad Faeiz,White William B.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference29 articles.

1. Predictors of readmission among elderly survivors of admission with heart failure;Krumholz;Am Heart J,2000

2. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry;Shindler;Am J Cardiol,1996

3. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology;Cubbon;Diab Vasc Dis Res,2013

4. Economic costs of diabetes in the U.S. in 2012;American Diabetes Association;Diabetes Care,2013

5. Assessing the cardiovascular safety of diabetes therapies;Goldfine;N Engl J Med,2008

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis;Cochrane Database of Systematic Reviews;2021-10-25

2. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms;Cardiovascular Research;2021-08-15

3. Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus;Drug Safety;2019-10-25

4. Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection;Medicinal Research Reviews;2018-05-28

5. Cardiovascular Effects of New Oral Glucose-Lowering Agents;Circulation Research;2018-05-11